University of Gabon Clinical Trial

Clinical Trials Against Hepatitis C

University of Gabon Medical Center Libreville, Republic of Gabon, and Cambodia AIDS and Protection Organization, Toulkok District Phnom Penh City, Cambodia. (Using Dr. LaPenta's Peptide Nucleic Acid Composition Improved And Patented by Dr. Kochel in 1998 - Immax A.)

Immunotherapy Against Hepatitis "C"

The data on the Gabon was very significant. You will note, however, there were no PCR's, because none were available at that location. The segregation of the patients into Hepatitis C group by HbsAg tests was more reliable than a simple clinical diagnosis (as was done in Cambodia).

You will note in all cases the UREA, Glycemia, ASAT, ALT, Bilirubin, and GGT returned to normal from very high levels with a 60 day period of time. As a result of all patients’ clinical signs returning to normal and Immax A, again showing no toxicity, these results are very promising.

This therapy may be a very valuable as an adjunct or replacement therapy to traditional therapy (Alpha Interferon + Ribavirin) or be used for those patients which cannot tolerate traditional therapy side effects or risk adverse reactions.

Click here for Clinical Trial Data

To learn more about Immune@work's products, please click here, call us at 1.734.437-5477,or email us at info@immuneatwork.com.